| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nicholas R Rensing, Dongjun Guo, Michael Won. Video-EEG monitoring methods for characterizing rodent models of tuberous sclerosis and epilepsy. Methods in molecular biology (Clifton, N.J.). vol 821. 2012-03-16. PMID:22125079. |
tuberous sclerosis complex (tsc) is a genetic disease involving dysregulation of the mtor pathway and resulting in disabling neurological manifestations, such as epilepsy. |
2012-03-16 |
2023-08-12 |
Not clear |
| Duyu Nie, Mustafa Sahi. A genetic model to dissect the role of Tsc-mTORC1 in neuronal cultures. Methods in molecular biology (Clifton, N.J.). vol 821. 2012-03-16. PMID:22125080. |
tuberous sclerosis complex (tsc) is an autosomal dominant disease caused by mutations in either of two genes, tsc1 or tsc2, whose protein products form a complex that is essential in the regulation of mammalian target of rapamycin (mtor) activity. |
2012-03-16 |
2023-08-12 |
Not clear |
| Hiroyuki Mori, Kun-Liang Gua. Tissue-specific ablation of Tsc1 in pancreatic beta-cells. Methods in molecular biology (Clifton, N.J.). vol 821. 2012-03-16. PMID:22125081. |
tuberous sclerosis complex 1 (tsc1) is a tumor suppressor that associates with tsc2 to inactivate rheb, thereby inhibiting signaling by the mammalian target of rapamycin (mtor) complex 1 (mtorc1). |
2012-03-16 |
2023-08-12 |
mouse |
| Xin Tong, Kimberly A Smith, Jill C Pellin. Apigenin, a chemopreventive bioflavonoid, induces AMP-activated protein kinase activation in human keratinocytes. Molecular carcinogenesis. vol 51. issue 3. 2012-03-09. PMID:21538580. |
although ampk is traditionally thought to play a major role in the regulation of cellular lipid and protein metabolism, recent discoveries reveal that ampk inhibits mammalian target of rapamycin (mtor) signaling and connects with several tumor suppressors such as liver kinase b1 (lkb1), p53, and tuberous sclerosis complex 2 (tsc2), indicating that ampk may be a potential target for cancer prevention and treatment. |
2012-03-09 |
2023-08-12 |
human |
| Mari Wataya-Kaneda, Mari Tanaka, Ayumi Nakamura, Shoji Matsumoto, Ichiro Katayam. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Archives of dermatology. vol 148. issue 1. 2012-03-06. PMID:22250258. |
a novel application of topical rapamycin formulation, an inhibitor of mtor, for patients with hypomelanotic macules in tuberous sclerosis complex. |
2012-03-06 |
2023-08-12 |
Not clear |
| Yoshihiro Tanaka, Joo Hyun Park, Pradeep S Tanwar, Tomoko Kaneko-Tarui, Shilpi Mittal, Ho-Joon Lee, Jose M Teixeir. Deletion of tuberous sclerosis 1 in somatic cells of the murine reproductive tract causes female infertility. Endocrinology. vol 153. issue 1. 2012-03-05. PMID:22128018. |
tumors develop with dysregulated activation of mammalian target of rapamycin (mtor), the kinase activity of which is kept in an inactive state by a tumor suppressor dimer containing tuberous sclerosis 1 (tsc1) and tsc2. |
2012-03-05 |
2023-08-12 |
mouse |
| Sharon S McDaniel, Michael Won. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neuroscience letters. vol 497. issue 3. 2012-03-02. PMID:21354266. |
mtor hyperactivation occurs in tuberous sclerosis complex (tsc), a common genetic cause of epilepsy, as a result of genetic mutations in upstream regulatory molecules. |
2012-03-02 |
2023-08-12 |
Not clear |
| Jane Yu, Andrey Parkhitko, Elizabeth Petri Hensk. Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM. Autophagy. vol 7. issue 11. 2012-02-22. PMID:21997371. |
mammalian target of rapamycin (mtor) complex 1 (mtorc1), which is activated in tuberous sclerosis complex (tsc) and lymphangioleiomyomatosis (lam), is a master regulator of cell growth, cellular metabolism, and autophagy. |
2012-02-22 |
2023-08-12 |
Not clear |
| Sandra L Dabora, David Neal Franz, Stephen Ashwal, Arthur Sagalowsky, Francis J DiMario, Daniel Miles, Drew Cutler, Darcy Krueger, Raul N Uppot, Rahmin Rabenou, Susana Camposano, Jan Paolini, Fiona Fennessy, Nancy Lee, Chelsey Woodrum, Judith Manola, Judy Garber, Elizabeth A Thiel. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PloS one. vol 6. issue 9. 2012-02-14. PMID:21915260. |
tuberous sclerosis (tsc) related tumors are characterized by constitutively activated mtor signaling due to mutations in tsc1 or tsc2. |
2012-02-14 |
2023-08-12 |
Not clear |
| Michael Haidinger, Johannes Werzowa, Thomas Weichhart, Marcus D Säeman. Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: killing 2 birds with 1 stone. Transplantation reviews (Orlando, Fla.). vol 25. issue 4. 2012-01-26. PMID:21419611. |
dysregulation and hyperactivation of the mammalian target of rapamycin (mtor) pathway define the molecular basis of the hamartoma syndromes, including cowden syndrome, tuberous sclerosis complex (tsc)/lymphangioleiomyomatosis, and peutz-jeghers syndrome. |
2012-01-26 |
2023-08-12 |
Not clear |
| M Rosner, M Hengstschläge. Nucleocytoplasmic localization of p70 S6K1, but not of its isoforms p85 and p31, is regulated by TSC2/mTOR. Oncogene. vol 30. issue 44. 2012-01-26. PMID:21602892. |
the tuberous sclerosis complex gene 2 (tsc2)/mammalian target of rapamycin (mtor) pathway controls many cellular functions via phosphorylation of ribosomal protein s6 kinases (s6ks). |
2012-01-26 |
2023-08-12 |
Not clear |
| M Wataya-Kaneda, M Tanaka, A Nakamura, S Matsumoto, I Katayam. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. The British journal of dermatology. vol 165. issue 4. 2012-01-23. PMID:21692771. |
dysregulation of mtor signalling by mutations in tuberin and/or hamartin leads to the formation of tuberous sclerosis complex (tsc). |
2012-01-23 |
2023-08-12 |
Not clear |
| Scott G Turner, Katherine B Peters, James J Vredenburgh, Annick Desjardins, Henry S Friedman, David A Reardo. Everolimus tablets for patients with subependymal giant cell astrocytoma. Expert opinion on pharmacotherapy. vol 12. issue 14. 2012-01-13. PMID:21806479. |
abnormal mammalian target of rapamycin (mtor) complex signaling and defects in tsc1 and tsc2 have been associated with the development of subependymal giant cell astrocytomas (segas) in tuberous sclerosis complex (tsc) patients. |
2012-01-13 |
2023-08-12 |
Not clear |
| David Neal Fran. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert review of anticancer therapy. vol 11. issue 8. 2012-01-10. PMID:21916571. |
everolimus: an mtor inhibitor for the treatment of tuberous sclerosis. |
2012-01-10 |
2023-08-12 |
Not clear |
| Masatoshi Kud. mTOR inhibitor for the treatment of hepatocellular carcinoma. Digestive diseases (Basel, Switzerland). vol 29. issue 3. 2011-12-27. PMID:21829022. |
mtor is located downstream in the pi3k/akt pathway, in which akt and the tuberous sclerosis complex (tsc) 1/2 are involved, to form a signal transduction pathway. |
2011-12-27 |
2023-08-12 |
human |
| C Nicole Sunnen, Amy L Brewster, Joaquin N Lugo, Fabiola Vanegas, Eric Turcios, Shivani Mukhi, Deena Parghi, Gabriella D'Arcangelo, Anne E Anderso. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia. vol 52. issue 11. 2011-12-19. PMID:21973019. |
increased activity of mtor complex 1 (mtorc1) has been demonstrated in cortical dysplasia and tuberous sclerosis complex, as well as in animal models of epilepsy. |
2011-12-19 |
2023-08-12 |
mouse |
| Kevin M Tierney, Deborah L McCartney, Jaco R Serfontein, Petrus J de Vrie. Neuropsychological attention skills and related behaviours in adults with tuberous sclerosis complex. Behavior genetics. vol 41. issue 3. 2011-12-15. PMID:21191642. |
tuberous sclerosis complex (tsc) is a genetic disorder associated with mtor over-activation and disruption of mapk, pi3k and ampk signalling. |
2011-12-15 |
2023-08-12 |
Not clear |
| Sutapa Banerjee, Nikkilina R Crouse, Ryan J Emnett, Scott M Gianino, David H Gutman. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proceedings of the National Academy of Sciences of the United States of America. vol 108. issue 38. 2011-12-12. PMID:21896734. |
in this regard, mutational inactivation of neurofibromatosis-1 (nf1), tuberous sclerosis complex (tsc), and pten genes is associated with glioma formation, such that pharmacologic inhibition of mtor signaling results in attenuated tumor growth. |
2011-12-12 |
2023-08-12 |
mouse |
| Carolyn L Buller, Charles W Heilig, Frank C Brosiu. GLUT1 enhances mTOR activity independently of TSC2 and AMPK. American journal of physiology. Renal physiology. vol 301. issue 3. 2011-12-07. PMID:21613414. |
in cells lacking functional tuberous sclerosis complex (tsc) 2, glut1 effects on mtor activity persisted, indicating that glut1 effects were not mediated by tsc. |
2011-12-07 |
2023-08-12 |
mouse |
| María C Gazzaneo, Renán A Orellana, Agus Suryawan, Alexander P Tuckow, Scot R Kimball, Fiona A Wilson, Hanh V Nguyen, Roberto M Torrazza, Marta L Fiorotto, Teresa A Davi. Differential regulation of protein synthesis and mTOR signaling in skeletal muscle and visceral tissues of neonatal pigs after a meal. Pediatric research. vol 70. issue 3. 2011-12-06. PMID:21654549. |
phosphorylation of tuberous sclerosis complex 2, proline-rich akt substrate of 40 kd, mtor, eukaryotic initiation factor 4e binding protein, and rp s6 kinase 1 increased in all tissues after feeding. |
2011-12-06 |
2023-08-12 |
Not clear |